Weekly Recap: H1 2026 finances and NSCLC Phase 1 79% 1—yr control, 33% GTV
Nanobiotix SA ADR (NASDAQ:NBTX) reported H1 2026 revenue plunged to €5.6M and a €34.3M net loss while cash of €110.9M funds operations into 2029, even as UT MD Anderson Phase 1 data for JNJ—1900 (NBTXR3) in NSCLC showed promising 1—yr locoregional control (79%), LPFS (61%) and OS (70%) with no Grad…